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Abstract: Review on soft tissue tumors with data on clinics, and the genes involved. 
 
Identity 
Note 
Soft tissue tumours represent a heterogeneous and 
complex group of mesenchymal lesions that may show 
a broad range of differentiation. Histologic 
classification is based upon morphologic demonstration 
of a specific line of differentiation. But, despite the 
extraordinary contribution of ancillary diagnostic 
techniques such as electron microscopy and 
immunohistochemistry, classification of mesenchymal 
neoplasms is still the subject of continuous debate. The 
true incidence of soft tissue tumors is nearly impossible 
to determine, especially for benign tumors, because 
many of these tumors are not biopsied. Soft tissue 
sarcomas compared with carcinomas and other 
neoplasms, constitute fewer than 1% of all cancers. 
Their morphological appearance is kaleidoscopic and 
varies. Hence, classification is often difficult and the 
subject of continuous debate among pathologists. 
For the purpose of uniformity the new World Health 
Organization (WHO) Classification of Tumors of Soft 
Tissue and Bone published in 2013 will be followed. A 
few new categories have been officially included in the 
Soft Tissue Tumour section: giant cell fibroblastoma, 
dermatofibrosarcoma protuberans, gastrointestinal 
stromal tumours and nerves sheath tumours. 
Undifferentiated/unclassified sarcomas are a new entity 
in this new edition. Ewing sarcoma and extraskeletal 
mensechymal chondrosarcoma, originally described in 
the Bone section is also included in this review. Benign 
uterine leiomyomas and endometrial stromal sarcoma 
are still included in the WHO Classification of Tumors 
Pathology and Genetics of Tumours of the Breast and  
Female Genital Organs. Moreover, a few new 
cytogenetic-molecular and histological correlations 
have been enclosed. 
Informations and (review) references are provided for 
well-characterized cytogenetic/molecular tumors 
investigated in more than a single case. For data 
regarding single case reported, the reader is referred to 
http://cgap.nci.nih.gov/Chromosomes/Mitelman; 2013. 
Clinics and pathology 
Disease 
Adipocytic tumors 
Cytogenetics 
Lipoma. More than half the cases studied show an 
abnormal karyotype, mostly balanced translocation, as 
single abnormality. Three distinct clustering of 
breakpoints have been distinguished: 1) the major 
group involving 12q13-15, with several possible 
partners, of which 3q27-28 is a preferential one; 2) a 
deletion/translocation of 13q11-q22; 3) a 
rearrangement of 6p21-23. The target gene in 12q14.3, 
HMGA2 (HMGIC) is a family member of the High 
Mobility Group (HMG) of protein. The most common 
gene fusion is HMGA2-LPP resulting from a 
t(3;12)(q27-28;q14.3). Other partners genes include: 
CXCR7 (2q37.3), EBF1 (5q33.3), NFIB (9p22.3), 
LHFP (13q13.3) and PPAP2 (1p32). Lipoma with 13q- 
show a minimal deleted region of 3.4 Mb, where only 
the C13orf11 is expressed in significant lower level 
compared with lipomas without 13q deletion. In lipoma 
with 6p21-23 rearrangement, the breaks occur adjacent 
to the coding sequences of HMGA1 (HMGIY), another 
member of the same HMG family. 
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Lipoblastoma. The characteristic cytogenetic feature is 
rearrangement of 8q11-13. This rearrangement is 
associated with promoter swapping, in which the 
PLAG1 promoter element is replaced by those of the 
hyaluronic acid synthase 2 (HAS2) or collagen 
(COL1A2) genes, at 8q24.3 and 7q21.3, respectively. 
The most common numerical is one or more extra 
copies of chromosome 8, with or without 8q11-13 
rearrangement. 
Angiolipoma. All cytogenetically investigated tumors, 
but one, have normal karyotypes. 
Chondroid lipoma. C11orf95 and MLK2 genes at 
11q13 and 16p13.3, respectively, are the genes 
involved in the t(11;16)(q13;p12-13). 
Spindle cell lipoma/Pleomorphic lipoma. Similar 
cytogenetic aberrations have been described in both 
entities. The most frequent losses are -13/13q-, 
followed by 16q22-qter, 6q14-21, 10p and 17p, and 
2q21-. 
Hibernoma. Involvement of 11q13 region has been 
described, with several translocation region partners, of 
which 9q34 and 14q11 are the most recurrent ones. 
However, FISH analysis demonstrated that these 
rearrangements are more complex than can be detected 
by conventional G-banding and interstitial deletions 
affect the seemingly normal chromosome 11. This 
deletion clusters to a 3 Mb region in 11q13 of the 132 
genes in this 3 Mb region. Several genes showed 
significant lower expression including MEN1, AIP, 
EHD1 and CDK2AP2. High expression was also seen 
with PPARA, PPARG, PPARGC1A and particularly 
with UCP1, compared with lipoma and white adipose 
tissue. 
Atypical lipomatous tumor/Well-differentiated 
liposarcoma. Supernumerary ring or/and giant marker 
chromosomes have been observed mostly as the sole 
chromosome aberration. Cells containing ring and/or 
giant markers varying in size or number can be 
observed in the same tumor sample. Telomeric 
associations are frequently seen. Molecular cytogenetic 
techniques indicate that both ring and giant marker 
chromosomes are composed of interspersed amplified 
sequences consistently originating from the 12q14-15 
region. The most consistently amplified gene is 
MDM2, usually accompanied by amplification of 
neighboring genes, such as CDK4, HMGA2, YEATS4, 
CPM, and FRS2. Additional chromosomal regions have 
shown to be co-amplified with 12q14-15, and with 
1q21-q25 being the most frequent region. These ring 
and giant marker chromosomes do not contain ana-
satellite sequences, but have "neocentromere". 
Dedifferentiated liposarcoma. Cytogenetic anomalies 
similar to those seen in atypical lipomatous tumors 
have been reported. Moreover, co-amplification 
involving mainly 1p32 and 6q23, which include JUN 
and its activate kinases ASK1 as target genes, has been 
demonstrated. 
Myxoid liposarcoma. The characteristic cytogenetic 
feature is t(12;16)(q13;p11), leading to the fusion of 
two genes DDIT3 (CHOP) and FUS (TLS). A rare 
variant translocation has been also described, 
t(12;22)(q13;q12), in which DDIT3 is fused with 
EWSR1. The absence of FUS/DDIT3 fusion in other 
morphologic mimics, such as myxoid well 
differentiated liposarcomas of the retroperitoneum and 
myxofibrosarcoma, has been demonstrated. 
Pleomorphic liposarcoma. High chromosome 
numbers with complex structural rearrangements have 
been often described. The absence of amplification of 
12q14-15 can help to distinguish pleomorphic 
liposarcoma from dedifferentiated liposarcoma. 
Disease 
Fibroblastic/Myofibroblastic tumors 
Cytogenetics 
Nodular fasciitis. The overexpression of USP6 gene in 
this lesion prompted to the identification of a USP6-
MYH9 gene fusion, as consequence of a cryptic 
t(17;22)(p13.3;q12.3). 
Angiofibroma of the soft tissue. Although this benign 
lesion was not included in the WHO 2013, a 
t(5;8)(p15;q13) associated with AHRR-NCOA2 gene 
fusion is the hallmark of this lesion. 
Proliferative fasciitis and proliferative myositis. For 
each of these entities, trisomy 2 has been reported in a 
single case. 
Elastofibroma. A significant chromosomal instability 
has been reported. Aberrations of the short arm of 
chromosome 1 were particularly noted. 
Juvenile hyaline fibromatosis. This lesion is caused 
by the inactivating mutation in the ANTXR2 gene 
encoding capillary morphogenesis protein 2, at 4q21. 
Fibroma of the tendon sheath. A single case with 
t(2;11)(q31-32;q12) has been reported. This 
translocation is apparently identical to the one reported 
on desmoplastic fibroblastoma. 
Desmoplastic fibroblastoma. A t(2;11)(q31-32;q12) 
or a 3-way variant has been observed. Deregulated 
expression of FOSL1 gene has been proposed as the 
functional outcome of the 11q12 rearrangement. 
Mammary-type fibroblastoma. Partial monosomy 
13q with or without partial monosomy 16q have been 
reported, similar to those described for spindle cell 
lipoma, and cellular angiofibroma, supporting a 
pathogenic link among these entities. 
Cellular angiofibroma. One single case reported with 
loss of 13 and 16, Interphase FISH showing deletion of 
RB1 and FOXO1 support this finding. 
Palmar/plantar fibromatoses. Near-diploid karyotype 
with simple numerical changes, particularly gain of 
chromosome 7 or 8 have been reported. 
Desmoid-type fibromatoses. Trisomies for 
chromosome 8 and/or 20 have been described in some 
cases. Rearrangement of 5q is found in desmoid tumors 
from patients with familial polyposis. APC inactivation 
has been reported in tumor arising in the setting of 
Gardner-type FAP. Mutations in the β-catenin 
Soft tissue tumors: an overview Dal Cin P 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(1) 59 
(CTNNB1) have been detected in 85% of sporadic 
lesions. 
Giant cell fibroblastoma. Only few cases have been 
analyzed by karyotyping, and either t(17;22)(q22;q13) 
or unbalanced t(17;22), has been observed in pediatric 
cases. This chromosome rearrangement is associated 
with COL1A1-PDGFB chimeric gene. Similar gene 
rearrangement has been identified in 
dermatofibrosarcoma protuberans. 
Dermatofibrosarcoma protuberans. A 
supernumerary ring/chromosome derived from a 
t(17;22)(q22;q13) is characteristic chromosome 
aberrations. This ring chromosome contains the 
centromeric region of chromosome 22, more than one 
copy of COL1A1-PDGFB gene fusion, and sometime, 
additional segments from other chromosomes. Clinical 
studies have shown a high response rate to imatinib 
therapy in both locally advanced and metastatic tumors, 
as imatinib blocks PDGFRB signaling. 
Extrapleural solitary fibrous tumor. After the 
publication of WHO13, a NAB2-STAT6 gene fusion 
was identified by next generation sequencing and has 
not been encountered in other soft-tissue tumors.  
This fusion result by a paracentric inversion on the 
12q13 region, where both NAB2 and STAT6 are genes 
closely adjacently located, overlapping 58 base pairs. 
Therefore this inversion is undetectable by standard G-
banding karyotyping, and only a minor fraction of the 
fusion-positive cases can be identified by FISH 
analysis. 
Inflammatory myofibroblastic tumor. Involvement 
of 2p23 occurs mainly or exclusively in children and 
young adults. Activation of the ALK receptor tyrosine 
kinase is accomplished by chromosomal translocation 
to a wide variety of partner genes, with TPM4 
(19p13.1), TPM3 (1q22.23), CLTCL2 (17q23), 
RANBP2 (2q13), ATIC (2q24), CARS (11p15) and 
SEC31L1 (4q21), being the most frequent.  
Of interest, the RANBP2-ALK gene fusion has an 
aggressive clinical course and shows a ALK immuno-
staining in a nuclear membrane pattern. Some of these 
ALK fusion genes have been observed in anaplastic 
large cell lymphoma and in diffuse large B-cell 
lymphoma. Moreover, ALK rearrangement has been 
also reported in a subgroup of non-small lung cancer, 
kidney tumors, esophageal squamous cell carcinoma.  
A fraction of all these cancer types shares activated 
ALK as the essential growth driver and such tumors 
can be targeted for treatment with ALK inhibitors e.g. 
Crizotinib. 
Myxoinflammatory fibroblastic sarcoma. Most of 
these lesions share a balanced or unbalanced 
t(1;10)(p22;q24-25).  
The breakpoints on this translocation are TGFBR3 in 
1p22 and MGEA5 in 10q24. However, no chimeric 
fusion transcript is detectable because these two genes 
are transcribed in opposite directions.  
Over-expression of FGF8 on 10q was identified by 
microarray analysis, suggesting that this translocation 
may alter gene transcription away from the breakpoint.  
The loss of material of the chromosome region 3p is 
associated with amplification of 3p11.1-12.1, 
containing VGLL3 gene. Similar t(1;10) abnormality 
has been also observed in hemosiderotic 
fibrolipomatous tumour. 
Infantile fibrosarcoma. A specific t(12;15)(p13;q26) 
is the hallmark of this tumor. Since the regions 
exchanged between chromosomes 12 and 15 are similar 
in size and banding characteristics, this translocation 
was overlooked in early reports, in which only 
numerical changes i.e. trisomies 11, 8, 17 and 20 were 
described. This translocation fuses the ETV6 (TEL) 
gene at 12p13 with the neurotrophin-3 receptor gene 
NTRK3 (TRKS) at 15q25.  
Notably, cellular congenital mesoblastic nephroma 
correlates with the presence of the same t(12;15) and 
with trisomy 11, but these findings are not seen in the 
classical congenital mesoblastic nephroma. The same 
t(12;15) has been reported in myeloid leukemia, 
secretory breast carcinoma, and mammary-type 
secretory carcinoma and salivary glands. 
Adult fibrosarcoma. No consistent abnormality has 
been detected among the complex karyotypes published 
to date. 
Myxofibrosarcoma. Highly complex karyotypes with 
extensive intratumoral heterogeneity have been 
reported. No consistent aberration has emerged. 
Low grade fibromyxoid sarcoma. A t(7;16)(q33;p11) 
is present in approximately two third of the cases, and a 
25% of the cases show a supernumerary ring 
chromosome.  
Both aberrations result by a FUS-CREB3L2 gene 
fusion. A rare variant t(11;16)(p11;p11) leading to a 
FUS-CREB3L1 gene fusion have been reported. 
Sclerosing epithelioid fibrosarcoma. FUS 
rearrangement is rarely detected in pure sclerotic 
epithelial fibrosarcoma, but it has been detected in low-
grade-fibromyxoid sarcoma with sclerosing  
 
epithelial fibrosarcoma-like loci. 
Disease 
So-called fibrohistiocytic tumors 
Cytogenetics 
Tenosynovial giant cell tumour, localized type. The 
most frequent translocation is the t(1;2)(p13;q35) and is 
associated with a CSF1-COL6A3 gene fusion, resulting 
in an over-expression of CSF1 in the neoplastic cells.  
No other CSF1 gene partners have yet been identified. 
The biologic evidence of a central role for CSF1 in the 
pathogenesis of these lesions is further supported by 
clinical experience, in which they responded 
therapeutically to imatinib. Involvement of 16q24 and 
trisomies 5 and/or 7 can also be observed. 
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Tenosynovial giant cell tumour, diffuse-type. The 
structural and numerical abnormalities described are 
similar to those observed in localized form, however 
trisomies for chromosomes 5 and 7 are more frequently 
encountered in the diffuse form of the tumor. 
Deep benign fibrous histiocytoma. A 
t(16;17)(p13.3;q21.3) was reported in a single case. 
Plexiform fibrohistiocytic tumor. No consistent 
abnormality has been detected among the 3 tumors so 
far reported. 
Giant cell tumors of the soft tissue. Multiple 
telomeric associations were reported in single case, like 
giant cell tumor of the bone. 
Disease 
Smooth muscle tumors 
Cytogenetics 
Leiomyosarcoma. Most karyotypes are complex and 
no consistent aberrations have been reported. However, 
some common gains or losses of genetic material have 
been detected by cytogenetic and comparative genomic 
hybridization (CGH) studies some aberrations may be 
more related to the site of origin than to the 
morphologic features of the tumors. Involvement of 
TP53, FANCA, RB, PTEN, MYOCD and ROR2 have 
been reported. 
Disease 
Pericytic (perivascular) tumors 
Cytogenetics 
Myopericytoma, including myofibroma. A small 
group of tumors considered to fall within the 
myopericytic category exhibits a t(7;12)(p22;q13) that 
results in the fusion of ACTB and GLI1 genes. 
Angioleiomyoma. Simple karyotypes with non-random 
structural aberration have been so far reported. 
Genomic array analysis showed that 22q11.2 is most 
common lost region, while the most gain is Xq arm. 
Disease 
Skeletal muscle tumors 
Cytogenetics 
Embryonal rhabdomyosarcoma. Complex karyotype 
are generally reported, including extra copies of 
chromosomes 2, 8 and 13, and rearrangements of 
chromosome 1. However, loss of heterozygosity of 
11p15 region is found in most of these tumors. 
Imprinted tumor suppressor genes i.e. IGF2, H19 and 
CDKN1C and HOTS have been suggested as the 
mechanism of tumorigenesis in these tumors. Several 
other individual genes have been also implicated in a 
subset of tumor e.g. RB1, TP53, RAS, GLI1, FGFR4, 
PIK3CA, CTNNB1, ALK. 
Alveolar rhabdomyosarcoma. A specific 
t(2;13)(q35;q14) characterizes this type of 
rhabdomyosarcoma. The genes involved are the PAX3 
gene on 2q35 and the FOXO1 gene on 13q14. A 
variant translocation has been described, 
t(1;13)(p36;q14), which fuses PAX7 gene on 1p36 with 
FOXO1. Tumors with PAX7-FOXO1 gene fusion 
transcript show a predilection for younger patients, 
appear in the extremities and have a better prognosis. 
An interesting distinctive feature of ARMS with the 
PAX7-FOXO1 is that the fusion gene is often 
duplicated or amplified. However, 20% of cases have 
neither t(2;13) nor t(1;13). Some of these cases have 
variant translocations involving either PAX or FOXO1 
(e.g., PAX-NCOA1, PAX3-AFX, FOXO1/FGFR1). 
Pleomorphic rhabdomyosarcoma. Highly complex 
karyotypes have been reported. 
Spindle cell/sclerosing rhabdomyosarcoma. 
PAC2/PAX7-FOXO1 fusions are virtually always 
absent. Pediatric cases of spindle cell 
rhabdomyosarcoma have recently been found to 
contain fusions of the NCOA2 gene at 8q13, with SRF 
or TEAD1. Therefore, this new correlation is not 
included in the WHO13. Adult spindle cell 
rhabdomyosarcoma do not appear to contain NCOA2 
rearrangement. 
Disease 
Vascular tumors 
Cytogenetics 
Kaposi sarcoma. No clinically relevant genetic 
changes have been reported. 
Pseudomyogenic hemangioendothelioma. A single 
case with a t(7;19)(q22;q13). 
Epithelioid hemangioendothelioma. A 
t(1;3)(p36.3;q25) has been associated with a 
rearrangement between CAMTA1 gene (at 1p36.3) and 
WWTR1 gene (at 3q25). This rearrangement has not 
been detected in any of the morphological mimics of 
epithelioid hemangioendothelioma, such as 
hemangioendothelioma, epithelioid  
 
angiosarcoma, or epithelioid sarcoma-like 
hemangioendothelioma. More recently, and therefore 
not reported in the WHO13, a small subset of EHE, 
with somewhat different morphology has been found to 
harbor TFE3 rearrangement, instead of the WWTR1-
CAMTA1 gene fusion. 
Angiosarcoma of the soft tissue. High level of MYC 
8q24 amplification is a consistent finding in radiation -
induced and lymphoedema -associated angiosarcoma. 
Co-amplification of FLT4 (5q35) can be also observed 
in 25% of secondary angiosarcoma. 
Disease 
Chondro-osseous tumors 
Cytogenetics 
Soft tissue chondroma. Three subgroups of 
chromosome rearrangements were observed so far: 1) 
rearrangement of 12q13-15, 2) trisomy 5 and 3) loss 
11q21-qter. Different HMGA2 involvements were 
reported on those chondromas with 12q13-q15 
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rearrangement, varying from amplification, truncated 
or full length HMGA2 transcript and HMGA2-LPP 
gene fusion transcript. 
Extraskeletal mesenchymal chondrosarcoma. A 
HEY1-NCOA2 gene fusion was detected by a genome-
wide screen of exon-level expression data in soft tissue 
as well as bone lesions. These genes are only ~10 Mb 
apart, and this fusion can be the results of a cryptic 
interstitial deletion or paracentric inversion between the 
8q13.3 and 8q21.1, that can easily be missed by G-
banded chromosome analysis.  
Extraskeletal osteosarcoma. No consistent 
abnormality has been detected among the 3 tumors 
studied to date. 
Gastrointestinal stromal tumour. Unlike the other 
sarcomas, oncogenic mutations play a central 
pathogenetic role in the gastrointestinal stromal tumors 
(GIST), rather than chromosomal rearrangements.  
KIT gene at 4q12 is mutated in 80-85% of cases. Most 
mutations are in exons 11 and 9, but mutations in exons 
13 and 17 have also been described. KIT in exon 9 
primary mutations often occur in tumors located 
predominantly in the small bowel and associated with 
an unfavorable clinical course.  
A subset of GISTs has mutations in the KIT-related 
PDGF receptor-α (PDGFRA) gene (also at 4q12), and 
shows a preference for gastric location, epithelioid 
morphology, and a more indolent clinical behavior. In 
about 10% of patients, no detectable mutations are 
identified in either KIT or PDGFRA are referred to as 
wild-type GIST. A subset of wild-type GIST harbor 
activatiing mutations in BRAF, or loss of succinate 
dehydrogenase complex by inactivating mutations.  
The subtype of exon 11 KIT mutations appears to have 
clinicopathologic relevance in GIST regarding tumor 
biology- e.g. Exon 11 deletions affecting codons 557 
and 558 predict a poor prognosis, bust most 
importantly, predicting reponse to therapy. Imatinib 
mesylate (GleevecTM), is a selective tyrosine kinase 
inhibitor whose targets include KIT, PDGFRA and 
ABL1.  
Imatinib treatment achieves a partial response or stable 
disease in about 80% of patients with metastatic GIST. 
GISTs with KIT exon 11 mutations are potently 
inhibited by imatinib, whereas those with KIT exon 9 
mutations are less responsive.  
GISTs with exon 11 mutations are most likely to 
respond to imatinib. However, acquired mutations, 
especially in exons 13 and 17, may confer secondary 
resistance to imatinib.  
Cytogenetically, GISTs show rather simple karyotypes 
with common losses of chromosomes 14 and 22, in 
most cases present as early events, regardless of the 
tumor site, clinical outcome, or KIT genotype.  
Additional chromosomal changes occur preferentially 
in high risk and recurrent GIST, including loss of 9p 
and 1p, among others. 
Disease 
Nerve sheath tumors 
Cytogenetics 
Schwannoma (including variants). Monosomy 
22/22q- is the most common chromosome aberration in 
classic and cellular schwannoma. Both NF2 and 
SMARCB1 (hSNF5, INI1) have been implicated on the 
tumorigenesis, as "four-hit" or "three-hit". Trisomy 17 
has been observed in plexiform cellular variants. 
Melanotic schwannoma. Amplification/deletion of 
2p16 region was demonstrated in 80% of lesions in 
patient with/without Carney complex. 
Neurofibroma (including variants). Inactivation of 
both copies of NF1 at 17q11.2 can occur in individuals 
with or without neurofibromatosis type I. 9p deletion 
containing CDKN2A, CDKN2B and MTAP has been 
frequently detected in localized intraneural and 
plexiform neurofibromas. 
Perineurioma. Monosomy 22/22q- is observed in 
these lesions targeting NF2 tumor suppressor gene. 
Additional 10q abnormalities have been identified in 
sclerosing variant. 
Malignant peripheral nerve sheath tumour. 
Complex karyotypes have been reported with 
numerical and structural rearrangements including: 1p, 
9p21 (CDKN2A), 10p, 11p, 13q14 (RB1), 17p13 
(TP53), 17q11.2 (NF1), 22q12.2 (NF2) as the most 
frequent chromosomal losses, and 7p, 7q, 8q, and 5q 
the most frequent chromosomal gains. These tumours 
are associated with bi-allelic inactivation of NF1, but 
their development requires additional mutations in 
CDKN2A or TP53, both in familial and sporadic cases. 
Disease 
Tumors of uncertain differentiation 
Cytogenetics 
Intramuscular myxoma. No consistent aberrations 
were observed in the 5 cases so far karyotyped. 
However, point mutations of GNAS are common in 
these lesions. 
Juxta-articular myxoma. One single case reported 
two unrelated abnormal clones. No GNAS mutations 
have been detected so far. 
Deep 'aggressive' angiomyxoma. Abnormalities of 
chromosome 12 have been reported. The most 
frequently rearranged chromosome region is 12q13-15 
and HMGA2 is the target gene either by generation of a 
fusion transcript or alteration affecting the 3' telomeric 
untranslated region.  
Angiomatoid fibrous histiocytoma. Three different 
translocations have been described: 1) 
t(12;16)(q13;p11) associated with ATF1-FUS fusion, 
2) t(12;22)(q13;q12) associated with EWSR1-ATF1 
gene fusion and 3) t(2;22)(q34;q12) associated with 
EWSR1-CREB1 gene fusion. Both t(12;22) and t(2;22) 
have also been reported in clear cell sarcoma. 
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Ossifying fibromyxoid tumor. The PHF1 gene at 
6p21, previously shown to be involved in some 
endometrial stromal tumors, is also recurrently 
rearranged in ossifying fibromyxoid lesions classified 
as typical or atypical. Loss of chromosome 22 has been 
observed in malignant lesions. 
Myoepithelioma/Myoepithelial carcinoma/Mixed 
tumour. EWSR1 (22q12) rearrangement have ben 
reported in approximately 50% of cases. The 
t(6;22)(p21;q12) involving EWSR1 and POU5F1 genes 
have been identified in a subset of deep seated tumors 
of extremities, in children or young adults with distinct 
clear cell morphology. The t(1;22)(q23;q12) involving 
EWSR1 and PBX1 genes has been identified in a 
subset of tumors with a deceptively bland appearance, 
composed mainly of spindle cells embedded in a 
fibrotic stroma, resembling in areas desmoid-type 
fibromatosis. A third translocation, t(19;22)(q13;q12) 
associated with EWSR1 and ZNF444 genes has been 
also identified in less than 2% of the cases, without any 
specific morphology. PLAG1 rearrangement was 
identified in a subset of EWSR1 negative myoepithelial 
tumors, more often benign, superficially located, and 
show ductal differentiation supporting a common 
pathogenesis with their salivary gland counterparts.  
Hemosiderotic fibrolipomatous tumour. Similar 
t(1;10)(p22;q24-25) and chromosome aberrations 
involving chromosome 3 with amplification of 3p11.1-
12 have been observed in myxoinflammatory 
fibroblastic sarcoma. 
Synovial sarcoma. A specific t(X;18)(p11.2;q11.2) 
characterizes both monophasic and biphasic 
morphologic variants. The vast majority of primary 
tumors show a near-diploid karyotype, while the 
recurring and metastasis lesions carry additional 
chromosome aberrations. Involvement of a third (or 
more) chromosome has been reported. The t(X;18) 
results in two gene fusions in which the SYT gene at 
18q11.2 joins either of two closely related genes at 
Xp11.2, designated SSX1 or SSX2. The monophasic 
variant exhibits SYT-SSX1 or SYT-SSX2 transcripts 
and the majority of the biphasic one SSX1. The 
formation of the respective fusions is generally 
mutually exclusive and remains constant during the 
course of the disease. There is also a moderate 
association of SS18-SSX1 gene fusion type with earlier 
distant recurrence and poorer metastasis-free survival 
in some studies, but not others. 
Epithelioid sarcoma. Complex karyotype, with 22q11-
12 aberrations involving SMARCB1. Gains of 8q, e.g. 
i(8q), have been observed in both classic and proximal 
types. 
Alveolar soft part sarcoma. A specific chromosome 
aberration, der(17)t(X;17)(p11;q25), is the hallmark of 
this sarcoma. This translocation fuses the TFE3 
transcription factor gene at Xp11.2 to a novel gene at 
17q25, designated as ASPL (ASPSCR1 or RCC17). Of 
interest, the balanced t(X;17)(p11.2;q25) has been also 
described in renal tumors of young people. 
Ewing sarcoma. The t(11;22)(q24;q12) was the first 
specific change to be defined in sarcoma. Secondary 
changes i.e. +8, +12 and der(16)t(1;16) were also 
frequently reported. The t(11;22) is associated with 
EWSR1-FLI1 fusion gene. However rare variant 
translocation have been reported, where the EWSR1 
gene fuses with different ETS-family gene partners 
such as the ERG gene at 21q22, the ETV1 at 7p22, 
E1AF at 17q12, FEV at 2q23. In addition cases with  
FUS-ERG or FUS-FEV gene fusions have been also 
rarely described. Variability in molecular transcripts 
has been reported, but the initial reported survival 
differences are no longer apparent with current 
treatment protocols. Secondary changes i.e. +8, +12, 
der(16)t(1;16), +20 were also frequently reported. 
Clear cell sarcoma of the soft tissue. The 
t(12;22)(q13;q12) is the more frequent cytogenetic 
change in this type of sarcoma and it is associated with 
EWSR1 (22q12) and ATF1 (12q13) genes. A 
t(2;22)(q34;q12) involving EWSR1 and CREB1 genes 
was detected almost exclusively in tumors of 
gastrointestinal (GI) tract. However, the clear cell 
sarcomas in GI tract with either EWSR1-ATF1 or 
EWSR1-CREB1 lack melanocytic markers, in contrast 
to the EWSR1-ATF1 soft tissue clear cell sarcoma. The 
spectrum of tumors with EWSR1-ATF1 and EWSR1-
CREB1 gene fusions has further expanded to include 
angiomatoid fibrous histiocytoma, hyalinizing clear cell 
carcinoma of the salivary gland, and primary 
pulmonary myxoid sarcoma. 
Extraskeletal myxoid chrondrosarcoma. A specific 
chromosomal abnormality, t(9;22)(q22;q12) 
characterizes this entity, though variant translocations 
have been also described. Variant translocations have 
been also reported: t(9;17)(q22;q11) and 
t(9;15)(q22;q21). All three translocations result in 
fusion of the NR4A3 (CHN, TEC) gene at 9q22 with 
the EWSR1 gene at 22q12, or with RBP56 gene at 
17q11 or with TCF12 gene at 15q21. 
Desmoplastic small round cell tumor. A specific 
chromosomal abnormality, t(11;22)(p13;q12) 
characterizes this entity, though variant translocations 
have been also described. The t(11;22) results in the 
fusions of two chromosomal region previously 
implicated in other malignant tumors: the Wilms tumor 
gene (WT1) localized to 11p13 and the Ewing sarcoma 
(EWSR1) gene localized to 22q12. 
Extrarenal rhabdoid tumor. Abnormalities of 
22q11.2, as translocations and deletions, have been 
described in these distinct tumors arising in any part of 
the human body. Mutations and homozygous deletions 
of the SMARCB1 gene have been detected. 
PEComas. These tumors are seen in the context of the 
Tuberous Sclerosis Complex syndrome caused by 
germline mutations in either TSC1 (OMIM: 191100) or 
TSC2 (OMIM: 613254).  
Sporadic PEComas often show complex karyotypes 
with loss of TSC2.  
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A smaller subset of PEComas, approximately 10%, 
harbors TFE3 fusions, but without TSC2 loss. 
Intimal sarcoma. Gain and amplification of 12q12-15, 
containing CDK4, TSPAN31, MDM2, GLI, and of 
4q21 containing PDGFRA and KIT (CD117) are the 
most constant genetic aberrations detected by CGH.  
EGFR amplification/polysomy has been also detected.  
Very frequently co-amplification or gains of PDGFRA, 
EGFR and MDM2 occur. 
Disease 
Undifferentiated/unclassified sarcomas 
Cytogenetics 
Undifferentiated round cell and spindle cell 
sarcomas. Two different entities have been reported : 
1) sarcomas with fusions of EWSR1 to non-ETS family 
transcription factor genes such as SP3, PATZ1, 
SMARCA5, POU5F1, NFATC2, often as single case; 
2) Ewing sarcoma-like tumours defined as "EWSR1-
fusion negative". Two distinct genetic events have been 
so far reported, both arising in children and young 
adults: a) either CIC-DUX4 gene fusion, resulting from  
t(4;19)(q35;q13) or t(10;19)(q26.3;q13) or b) a BCOR-
CCNB3 gene fusion, as the result of a paracentric 
inversion on the short arm (p) of the X-chromosome. 
Undifferentiated pleomorphic sarcoma. High-grade 
pleomorphic sarcomas, including many tumors 
formerly called MFH, generally have complex and 
nondistinctive karyotype and may represent the most 
undifferentiated state of other sarcomas. Those 
undifferentiated sarcomas with 12q12-15 amplification 
including MDM2 and CDK4, are now classified as 
dedifferentiated liposarcoma. 
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